ID   PICAT
AC   CVCL_ZI14
DR   cancercelllines; CVCL_ZI14
DR   Wikidata; Q98128587
RX   PubMed=6278187;
RX   PubMed=6278188;
CC   Population: African; Nigerian.
CC   Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2676 ! P3HR-1
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 02-05-24; Version: 8
//
RX   PubMed=6278187; DOI=10.1093/jnci/68.2.179;
RA   Zeuthen J., Klein G., Ber R., Masucci G., Bisballe S., Povey S.,
RA   Terasaki P.I., Ralph P.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I.
RT   Isolation, characterization, cell surface markers, and B-cell
RT   markers.";
RL   J. Natl. Cancer Inst. 68:179-195(1982).
//
RX   PubMed=6278188; DOI=10.1093/jnci/68.2.197;
RA   Klein G., Zeuthen J., Ber R., Ernberg I.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II.
RT   Epstein-Barr virus induction patterns.";
RL   J. Natl. Cancer Inst. 68:197-202(1982).
//